Bini Chemicals And Pharmaceuticals International Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 28-06-2024
- Paid Up Capital ₹ 5.00 M
as on 28-06-2024
- Company Age 22 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 48.76%
(FY 2022)
- Profit 57.79%
(FY 2022)
- Ebitda 54.32%
(FY 2022)
- Net Worth 25.24%
(FY 2022)
- Total Assets 27.17%
(FY 2022)
About Bini Chemicals And Pharmaceuticals International
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M, as per Ministry of Corporate Affairs (MCA) records.
Binita Shah and Dharmesh Shah serve as directors at the Company.
- CIN/LLPIN
U51397MH2002PTC136753
- Company No.
136753
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Aug 2002
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Bini Chemicals And Pharmaceuticals International?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Binita Shah  | Director | 07-Aug-2002 | Current |
| Dharmesh Shah | Director | 07-Aug-2002 | Current |
Financial Performance of Bini Chemicals And Pharmaceuticals International.
Bini Chemicals And Pharmaceuticals International Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 48.76% increase. The company also saw a substantial improvement in profitability, with a 57.79% increase in profit. The company's net worth Soared by an impressive increase of 25.24%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bini Chemicals And Pharmaceuticals International?
In 2021, Bini Chemicals And Pharmaceuticals International had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Bdr Pharmaceuticals International Private LimitedActive 22 years 2 monthsDharmesh Shah is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Bini Chemicals And Pharmaceuticals International?
Unlock and access historical data on people associated with Bini Chemicals And Pharmaceuticals International, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bini Chemicals And Pharmaceuticals International, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bini Chemicals And Pharmaceuticals International's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
